Ceapro Inc Aktie
Kurs
Kursziel
-
-
-
-
-
-
Gib deine Einschätzung ab, um die Meinung der Community zu sehen!
sharewise basiert auf der Weisheit der Vielen. Diese funktioniert am Besten, wenn man nicht durch die Einschätzungen der anderen Mitglieder beeinflusst ist. Bitte klicke einen Button an, dann siehst Du sofort, wie die Community abgestimmt hat.
Deine Einschätzung
Was spricht für und gegen Ceapro Inc in den nächsten Jahren?
Pro
?
A****************
?
M****
?
M************
Kontra
?
W******* i* V********
?
U****************
?
L*********** I********** f** d** n******* J****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Ceapro Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Ceapro Inc | - | - | - | - | - | - | - |
| AEterna Zentaris Inc. | -2,17 % | 0,00 % | -1,80 % | -37,61 % | 5,96 % | -90,43 % | -97,95 % |
| Satellos Bioscience Inc. | - | -6,71 % | -0,65 % | -36,78 % | 10,87 % | -76,09 % | - |
| Burcon Nutrascience Corp. | 6,29 % | -0,65 % | -33,62 % | -12,50 % | 15,79 % | -95,38 % | -21,43 % |
Kommentare
... EDMONTON, Alberta, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (CRPOF) (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2021.
“Progress continues on all fronts from production operations to research and development, allowing us to advance our pipeline while expanding our business model. With our newly formed network of highly renowned experts from University of Alberta, McMaster University, the Montreal Heart Institute, and the Angiogenesis Foundation, we have implemented a comprehensive strategic research plan that we believe enables us to address immune/inflammation-based and lifestyle diseases at various stages and from all angles. Additionally, with upcoming results expected in the fourth quarter of this year for Ceapro’s very first clinical trial, I believe we are well positioned for the next steps in becoming a premier life sciences company. The Company has exciting things on the horizon and we are committed to building on momentum,” stated Gilles Gagnon, M.Sc., MBA, President and CEO. ...
https://seekingalpha.com/pr/18450393-ceapro-inc-reports-2021-second-quarter-and-six-month-financial-results-and-operational
https://seekingalpha.com/pr/18450393-ceapro-inc-reports-2021-second-quarter-and-six-month-financial-results-and-operational
